To view this email as a web page, click here. |
|
 |
NPs and PAs in Dermatology |
|
|
|
|
In partnership with the Dermatology Education Foundation, view featured articles from Dermatology Times with expert NP and PA commentary.
|
Commentary
|
In this edition of Clinical Considerations, we examine a new treatment for hyperhidrosis, the effectiveness of Melasma treatments, and what to keep in mind when making a syphilis treatment.
Read Joe Gorelick's takeaways.
|
CLINICAL CONSIDERATIONS
|
|
In June, Dermira announced safety and efficacy results of two phase 3 pivotal trials for DRM04, an investigational topical anticholinergic product in development for patients with primary axillary hyperhidrosis.
Take a look at the study. |
|
Agents that can attack melasma on multiple fronts include retinoids, glucosamine, hydroquinone, topical steroids, phytosterol, glycyrrhetinic acid, niacinamide, soybean extracts, retinoids, salicylic acid and liquirtin, an expert says.
Read more. |
|
Syphilis has made a resurgence in the U.S., with the number of new cases increasing annually for the last 15 years. New screening recommendations identify patient populations that require at least annual screenings. An expert discusses what all of this means for dermatologists.
Here are the implications. |
|
|
Click to contact the editorial team. Click to contact the sales team. |
|
Part of the |
 |
|
|
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply.
Please use the links provided if you have questions or concerns regarding this email or your subscription. |
|
|
